Background: Serum S100 protein has been known to reflect the severity of brain damage. The purpose of this study was to compare the degree of brain damage based on the serum S100 protein level between aneurysm clipping and coiling groups and to evaluate the prognostic value of S100 protein in patients with subarachnoid hemorrhage (SAH). Methods: Serum S100 protein was measured by Elecsys S100 immunoassay at admission, and at 6 and 24 h, and days 3 and 5 postoperatively for 100 consecutive SAH patients (clipping group: 56, coiling group: 44) and for 74 healthy controls. Hunt-Hess grade (HHG), Fisher grade (FG), the presence of intraventricular (IVH) or intracerebral hemorrhage (ICH), and outcome at discharge were evaluated. The time course of serum S100 was compared between the groups. The prognostic value of S100 protein was evaluated by logistic regression analysis. Results: The median S100 level in SAH patients on admission was significantly higher than in healthy controls (0.081 vs. 0.05 µg/l, p < 0.0001) and it was also higher as HHG and FG increased (p < 0.0001). Logistic regression analysis revealed that only the S100 value at admission was an independent prognostic factor for poor outcomes after adjusting for age, sex, HHG, presence of IVH or ICH, and treatment modality (OR: 100.5, 95% CI: 1.65–6,053.61). The baseline S100 value of 0.168 predicted poor outcomes with a sensitivity of 75% and a specificity of 83%. The time course of the median S100 level peaked at 6 h and then decreased serially in both clipping and coiling groups. However, the degree of S100 elevation was marked in the clipping group, especially at 6 h postoperatively (0.177 vs. 0.116 µg/l, p = 0.022), suggesting more severe brain damage in the clipping group. In the coiling group, the S100 value was significantly higher in patients who showed high signal intensity lesions in diffusion-weighted images, suggesting ischemic brain damage. Furthermore, even in patients who were categorized as good clinical grade at admission and as good outcome at discharge, the median S100 values at 6 and 24 h postoperatively were significantly higher in the clipping group than in the coiling group (p < 0.05). Conclusion: The initial S100 protein value is an independent prognostic factor for poor outcomes in SAH patients. Based on the S100 protein level, aneurysm clipping seems to provoke more brain damage than aneurysm coiling. Endovascular coiling should be considered the first therapeutic option for aneurysmal SAH patients.

Keywords:
S100 protein, Subarachnoid hemorrhage, Clipping, Coiling, Prognosis, Brain damage
1.
Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965;19:739–744.
2.
Sedaghat F, Notopoulos A: S100 protein family and its application in clinical practice. Hippokratia 2008;12:198–204.
3.
Dyck RH, Van Eldik LJ, Cynader MS: Immunohistochemical localization of the S-100 beta protein in postnatal cat visual cortex: spatial and temporal patterns of expression in cortical and subcortical glia. Brain Res Dev Brain Res 1993;72:181–192.
4.
Mercier F, Hatton GI: Immunocytochemical basis for a meningeo-glial network. J Comp Neurol 2000;420:445–465.
5.
Ludwin SK, Kosek JC, Eng LF: The topographical distribution of S-100 and GFA proteins in the adult rat brain: an immunohistochemical study using horseradish peroxidase-labelled antibodies. J Comp Neurol 1976;165:197–207.
6.
Abdul-Khaliq H, Alexi-Meskhishvili V, Lange PE: Serum S-100 protein levels after pediatric cardiac surgery: a possible new marker for postperfusion cerebral injury. J Thorac Cardiovasc Surg 1999;117:843–844.
7.
Blomquist S, Johnsson P, Luhrs C, Malmkvist G, Solem JO, Alling C, Stahl E: The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. J Cardiothorac Vasc Anesth 1997;11:699–703.
8.
Lloyd CT, Ascione R, Underwood MJ, Gardner F, Black A, Angelini GD: Serum S-100 protein release and neuropsychologic outcome during coronary revascularization on the beating heart: a prospective randomized study. J Thorac Cardiovasc Surg 2000;119:148–154.
9.
Hachimi-Idrissi S, Zizi M, Nguyen DN, Schiettecate J, Ebinger G, Michotte Y, Huyghens L: The evolution of serum astroglial S-100 beta protein in patients with cardiac arrest treated with mild hypothermia. Resuscitation 2005;64:187–192.
10.
Ingebrigtsen T, Romner B, Marup-Jensen S, Dons M, Lundqvist C, Bellner J, Alling C, Borgesen SE: The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 2000;14:1047–1055.
11.
Korfias S, Stranjalis G, Papadimitriou A, Psachoulia C, Daskalakis G, Antsaklis A, Sakas DE: Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006;13:3719–3731.
12.
Mussack T, Kirchhoff C, Buhmann S, Biberthaler P, Ladurner R, Gippner-Steppert C, Mutschler W, Jochum M: Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med 2006;44:1140–1145.
13.
Abraha HD, Butterworth RJ, Bath PM, Wassif WS, Garthwaite J, Sherwood RA: Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997;34:366–370.
14.
Butterworth RJ, Sherwood RA, Bath PM: Serum S-100 protein in acute stroke. Stroke 1998;29:730.
15.
Elting JW, de Jager AE, Teelken AW, Schaaf MJ, Maurits NM, van der Naalt J, Sibinga CT, Sulter GA, De Keyser J: Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000;181:104–110.
16.
Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M: Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005;62:1130–1134.
17.
Missler U, Wiesmann M, Friedrich C, Kaps M: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956–1960.
18.
Delgado P, Alvarez Sabin J, Santamarina E, Molina CA, Quintana M, Rosell A, Montaner J: Plasma S100B level after acute spontaneous intracerebral hemorrhage. Stroke 2006;37:2837–2839.
19.
Brea D, Sobrino T, Blanco M, Cristobo I, Rodriguez-Gonzalez R, Rodriguez-Yanez M, Moldes O, Agulla J, Leira R, Castillo J: Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke. Clin Chem Lab Med 2009;47:1513–1518.
20.
Weiss N, Sanchez-Pena P, Roche S, Beaudeux JL, Colonne C, Coriat P, Puybasset L: Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology 2006;104:658–666.
21.
Oertel M, Schumacher U, McArthur DL, Kastner S, Boker DK: S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci 2006;13:834–840.
22.
Wiesmann M, Missler U, Hagenstrom H, Gottmann D: S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 1997;139:1155–1160.
23.
Moritz S, Warnat J, Bele S, Graf BM, Woertgen C: The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J Neurosurg Anesthesiol 2010;22:21–31.
24.
Sanchez-Pena P, Pereira AR, Sourour NA, Biondi A, Lejean L, Colonne C, Boch AL, Al Hawari M, Abdennour L, Puybasset L: S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit Care Med 2008;36:2267–2273.
25.
Yoon SM, Choi YJ, Kim HJ, Shim JJ, Bae HG, Yun IG: Prognostic value of serum S100 protein by Elecsys s100 immunoassay in patients with spontaneous subarachnoid and intracerebral hemorrhages. J Korean Neurosurg Soc 2008;44:308–313.
26.
Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R: International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2,143 patients with ruptured intracranial aneurysms: a randomized trial. J Stroke Cerebrovasc Dis 2002;11:304–314.
27.
Proust F, Martinaud O, Gerardin E, Derrey S, Leveque S, Bioux S, Tollard E, Clavier E, Langlois O, Godefroy O, Hannequin D, Freger P: Quality of life and brain damage after microsurgical clip occlusion or endovascular coil embolization for ruptured anterior communicating artery aneurysms: neuropsychological assessment. J Neurosurg 2009;110:19–29.
28.
Moman MR, Verweij BH, Buwalda J, Rinkel GJ: Anosmia after endovascular and open surgical treatment of intracranial aneurysms. J Neurosurg 2009;110:482–486.
29.
Bellebaum C, Schafers L, Schoch B, Wanke I, Stolke D, Forsting M, Daum I: Clipping versus coiling: neuropsychological follow up after aneurysmal subarachnoid haemorrhage (SAH). J Clin Exp Neuropsychol 2004;26:1081–1092.
30.
Hutter BO, Kreitschmann-Andermahr I, Mayfrank L, Rohde V, Spetzger U, Gilsbach JM: Functional outcome after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 1999;72:157–174.
31.
Stranjalis G, Korfias S, Psachoulia C, Kouyialis A, Sakas DE, Mendelow AD: The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir (Wien) 2007;149:231–237, discussion 237–238.
32.
Wiesmann M, Missler U, Gottmann D, Gehring S: Plasma S-100B protein concentration in healthy adults is age- and sex-independent. Clin Chem 1998;44:1056–1058.
33.
Muller K, Elverland A, Romner B, Waterloo K, Langbakk B, Unden J, Ingebrigtsen T: Analysis of protein S-100B in serum: a methodological study. Clin Chem Lab Med 2006;44:1111–1114.
34.
De Vries J, Snels SE, Menovsky T, Lemmens WA, De Reus H, Lamers KJ, Grotenhuis JA: Peri-operative levels of s-100 protein in serum: marker for surgical manipulation and postoperative complications. Minim Invasive Neurosurg 2003;46:33–36.
35.
Jonsson H, Johnsson P, Hoglund P, Alling C, Blomquist S: Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 2000;14:698–701.
36.
Jonsson H, Johnsson P, Alling C, Backstrom M, Bergh C, Blomquist S: S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome. Ann Thorac Surg 1999;68:2202–2208.
37.
Chung SW, Baik SK, Kim Y, Park J: Thromboembolic events after coil embolization of cerebral aneurysms: prospective study with diffusion-weighted magnetic resonance imaging follow-up. J Korean Neurosurg Soc 2008;43:275–280.
38.
Soeda A, Sakai N, Murao K, Sakai H, Ihara K, Yamada N, Imakita S, Nagata I: Thromboembolic events associated with Guglielmi detachable coil embolization with use of diffusion-weighted MR imaging. Part II. Detection of the microemboli proximal to cerebral aneurysm. AJNR Am J Neuroradiol 2003;24:2035–2038.
39.
Passier PE, Visser-Meily JM, van Zandvoort MJ, Post MW, Rinkel GJ, van Heugten C: Prevalence and determinants of cognitive complaints after aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2010;29:557–563.
40.
Vieira AC, Azevedo-Filho HR, Quinino S, Ponte de Souza ML, Camara D Jr, Leitao L, Andrade G: Language, memory, and verbal fluency changes in patients with aneurysmal subarachnoid hemorrhage: results of a preoperative investigation. World Neurosurg 2011;75:653–659; discussion 596–597.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.